Figure 1.

VSV-hgp100+ACT Treatment Strategy Controls Disseminated Disease

(A) Mice were challenged first s.c. tumor and i.v. tumor. When the s.c. tumor was visible (day 6–8), CD8⁺ Pmel T cells were adoptively transferred into the mice. Beginning on day 7–9, and continuing three times per week, the mice received a total of six doses of VSV-hgp100 or PBS. (B) Mice challenged with s.c. and i.v. B16-OVA received the treatment schedule above, in addition to a second Pmel treatment on day 21 following tumor challenge. n = 10 mice/group. (C) Subcutaneous tumor volumes measured three times weekly with calipers. Each line represents an individual mouse, grouped by treatment. (D) Mice challenged s.c. and i.v. with B16 cells received the treatment schedule above. n = 11 mice/group. (E) Subcutaneous tumor volumes measured three times weekly with calipers. Each line represents an individual mouse grouped by treatment. The significance for overall survival was determined at p < 0.01.